Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss

C. Castelo-Branco,M. J. Cancelo Hidalgo,S. Palacios,M. Ciria-Recasens,A. Fernández-Pareja,C. Carbonell-Abella,J. Manasanch,J. Haya-Palazuelos
DOI: https://doi.org/10.1080/13697137.2019.1685488
2019-11-21
Climacteric
Abstract:<span><b>Objective:</b> This study aimed to compare the efficacy and safety of ossein-hydroxyapatite complex (OHC) versus calcium carbonate (CC) for preventing bone loss during perimenopause in current clinical practice.<b>Methods:</b> The prospective, comparative, non-randomized, open-label study included 851 perimenopausal women with basal bone mineral density (BMD) <i>T</i>-score ≥−2 standard deviations (SDs). Participants received either OHC (712 mg calcium/day) or CC (1000 mg calcium/day) over 3 years. BMD was evaluated by dual-energy X-ray absorptiometry at the lumbar spine (L2–L4) at baseline and after 18 and 36 months of follow-up. Adverse drug reactions (ADRs) were also recorded.<b>Results:</b> In women receiving OHC, BMD at the L2–L4 site remained stable over the 3-year follow-up period (mean [SD] change 0.00 [0.11] g/cm<sup>2</sup>). BMD in the CC arm decreased −3.1% (mean [SD] − 0.03 [0.11] g/cm<sup>2</sup>). Between-group differences were statistically significant (<i>p</i> &lt; 0.001) and favored OHC. ADRs were more frequent in the CC group (7.7% vs. 2.7% in the OHC group; <i>p</i> = 0.001), affecting primarily the gastrointestinal system.<b>Conclusion:</b> OHC showed greater efficacy and tolerability than CC for bone loss prevention in perimenopausal women in real-world practice. As the daily dose of calcium was higher in the CC group, the differences might be linked to the ossein compound in OHC.</span>
obstetrics & gynecology
What problem does this paper attempt to address?